[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Affiliated Cancer Hospital & Institute of Guangzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":284},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,65,83,113,141,167,193,211,233,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100640780","a-prospective-study-on-the-diagnosis-of-malignant-tumors-with-18f-fgin-petct-100640780",false,"NCT07602569","A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET\u002FCT","Inclusion Criteria:\n\n1. Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives)\n2. Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET\u002FCT or 18F-FGln PET\u002FCT to determine the most appropriate treatment strategy\n3. Patients without other tumor history\n4. Patients with good compliance, providing informed consent, and able to follow the research protocol\n\nExclusion Criteria:\n\n1. pregnant or lactating patients or patients under 18 years old\n2. the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent;\n3. patients with poor compliance, unable to tolerate or cooperate with PET\u002FCT examinations.\n4. those who have undergone gastrointestinal barium meal examination within one week;\n5. other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial","ALL","18 Years","70 Years",{"count":19,"type":20},110,"ESTIMATED","6 Months","OBSERVATIONAL","Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET\u002FCT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET\u002FCT in patients with various types of malignant tumors.",[25],"Cancer (With or Without Metastasis)",[27],"cancer","RECRUITING","2026-05-16",{"date":31,"type":32},"2026-05-22","ACTUAL",{"date":34,"type":32},"2025-10-20",{"date":36,"type":20},"2028-12-01",{"name":38,"class":39},"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100614949","phase-2-ql1706-combined-with-chemotherapy-and-anlotinib-for-the-treatment-of-recurrent-ovarian-cancer-100614949","NCT07286240","QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","A Single-arm, Multicenter Phase II Clinical Study of QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* 1.Capable of understanding and voluntarily signing the written Informed Consent Form (ICF); the ICF must be signed before any study-specific procedures are performed.\n\n  2.Female, aged 18-70 years at the time of ICF signature. 3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4.Life expectancy ≥ 3 months. 5.Histologically confirmed epithelial ovarian cancer (including fallopian-tube and primary peritoneal carcinoma) that has recurred after standard platinum-based therapy:\n  1. Platinum-sensitive relapse (recurrence ≥ 6 months after completion of the last platinum-based therapy).\n  2. Platinum-resistant relapse (recurrence \\\u003C 6 months after completion of the last platinum-based therapy or progression while on PARP-inhibitor maintenance).\n\n     Note: Maintenance PARP inhibitor or bevacizumab after CR\u002FPR to prior chemotherapy, and hormonal therapy, are not counted as additional lines of therapy.\n\n     6.At least one measurable lesion per RECIST v1.1. Lesions previously irradiated or treated with other loco-regional therapy can serve only as non-target lesions unless clear progression is documented or tumor viability is biopsy-proven.\n\n     7.Archived or freshly obtained tumor tissue (primary or relapse) must be available for biomarker analyses. Five unstained formalin-fixed paraffin-embedded (FFPE) slides or a tissue block are required for central PD-L1 testing (slides preferred). If re-biopsy is judged unsafe, the number of slides may be reduced after discussion with the medical monitor.\n\n     8.Adequate organ function at screening:\n\n     Hematology:\n\n     Hb ≥ 90 g\u002FL ANC ≥ 1.5 × 10⁹\u002FL PLT ≥ 100 × 10⁹\u002FL\n\n     Biochemistry:\n\n     Albumin ≥ 29 g\u002FL ALT\u002FAST \\\u003C 3 × ULN (\\\u003C 5 × ULN if liver metastases) TBIL ≤ 1.5 × ULN Creatinine ≤ 1.5 × ULN 9.Women of child-bearing potential must have a negative serum pregnancy test within 3 days before first dose. If sexually active with a non-sterilized male partner, they must use a highly effective contraceptive method from screening until 6 months after the last study-dose; rhythm or withdrawal methods are not acceptable.\n\n     10.The need for additional cytoreductive surgery is at the investigator's discretion.\n\n     Exclusion Criteria:\n* 1.Non-epithelial ovarian malignancies (e.g., carcinosarcoma, sex-cord stromal tumors).\n\n  2.Central-nervous-system metastases or meningeal carcinomatosis. 3.Pleural, pericardial, or ascitic effusions requiring repeat drainage \\> once per month.\n\n  4.Active malignancy within 3 years before first dose, except locally curable cancers deemed cured (e.g., squamous- or basal-cell skin cancer, superficial bladder cancer, ductal carcinoma in situ of breast).\n\n  5.Prior systemic anti-cancer therapy within 3 weeks (chemotherapy, bevacizumab\u002Fbiosimilars, TKI, PARP inhibitor); palliative radiotherapy or immunomodulators (e.g., thymosin, interferon, IL-2) or cancer-treating Chinese patent medicines (e.g., Aidi injection) within 2 weeks; hormonal agents (e.g., tamoxifen, letrozole) within 1 week.\n\n  6.Previous immune-checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.) or agonists of immune co-stimulatory molecules (ICOS, CD40, CD137, GITR, OX40, etc.).\n\n  7.Major surgery, open biopsy, or significant trauma within 4 weeks; elective major surgery planned during study.\n\n  8.Active or likely recurrent autoimmune disease (exceptions: vitiligo, alopecia, psoriasis\u002Feczema not requiring systemic therapy; hypothyroidism from autoimmune thyroiditis on stable replacement; type 1 diabetes on stable insulin).\n\n  9.Systemic corticosteroids \\> 10 mg\u002Fday prednisone equivalent or other immunosuppressants within 14 days (inhaled, ophthalmic, or topical steroids ≤ 10 mg\u002Fday permitted).\n\n  10.Live vaccine within 4 weeks. 11.Primary or secondary immunodeficiency, including positive HIV antibody. 12.Prior solid-organ or allogeneic hematopoietic-stem-cell transplant. 13.History of interstitial lung disease or non-infectious pneumonitis. 14.Severe infection within 4 weeks (complicated infection requiring hospitalization, sepsis, severe pneumonia).\n\n  15.Active infection requiring systemic therapy (including active TB or active syphilis) or systemic antibiotics\u002Fantivirals\u002Fantifungals within 2 weeks (except suppressive anti-HBV therapy).\n\n  16.Active hepatitis B (HBsAg-positive with HBV DNA \\> 1000 IU\u002FmL); active hepatitis C. Inactive HBV carriers with HBV DNA ≤ 1000 IU\u002FmL are eligible. Subjects with cured HCV (HCV Ab-positive and HCV RNA-negative) are eligible.\n\n  17.Inflammatory bowel disease (Crohn's, ulcerative colitis), active diverticulitis, clinical bowel obstruction, or need for parenteral hydration\u002Fnutrition or nasogastric tube.\n\n  18.Significant cardiovascular\u002Fcerebrovascular disease:\n  1. MI, unstable angina, pulmonary embolism, aortic dissection, DVT, arterial thrombo-embolism within 6 months\n  2. NYHA class ≥ II heart failure\n  3. Serious arrhythmia requiring chronic therapy (stable-rate asymptomatic atrial fibrillation allowed)\n  4. CVA within 6 months\n  5. LVEF \\\u003C 50 %\n  6. Prior myocarditis\u002Fcardiomyopathy; uncontrolled hypertension (\\> 150\u002F100 mmHg) or hypertensive crisis\u002Fencephalopathy 19.Peripheral neuropathy ≥ grade 2 (NCI CTCAE v5.0). 20.Unresolved toxicity \\> grade 1 from prior anti-cancer therapy (except alopecia).\n\n     21.Severe hypersensitivity to any monoclonal antibody. 22.Pregnancy or lactation. 23.Any condition that, in the investigator's opinion, would compromise safety, interfere with study evaluations, or confound results (e.g., severe concomitant disease or psychiatric disorder).\n\n     24.Known hypersensitivity to any study drug or excipient. 25.Prior gastrointestinal perforation, intra-abdominal abscess, or bowel obstruction within 3 months or radiologic\u002Fclinical evidence of obstruction.\n\n     26.Hypertension inadequately controlled on medication (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg).\n\n     27.Coagulopathy (INR \\> 2.0 or PT \\> 16 s), bleeding diathesis, or thrombolytic\u002Fanticoagulant therapy (prophylactic low-dose aspirin or LMWH allowed).\n\n     28.Clinically significant bleeding or bleeding tendency within 3 months (e.g., GI bleeding, hemorrhagic gastritis, vasculitis).\n\n     29.Arterial or venous thrombosis within 6 months (CVA, TIA, intracranial bleed, DVT, PE); superficial vein thrombosis may be allowed at investigator's discretion.\n\n     30.Hereditary or acquired bleeding\u002Fthrombotic disorders (e.g., hemophilia, coagulation defects, thrombocytopenia).\n\n     31.Active ulcer, non-healing wound, or fracture. 32.Urine protein ≥ ++ confirmed by 24-h urine protein \\> 1.0 g. 33.Prior palliative radiotherapy to \\> 5 % of bone-marrow area within 4 weeks. 34.Strong CYP3A4 inducers within 2 weeks or strong CYP3A4 inhibitors within 1 week.\n\n     35.Prior treatment with anlotinib or other small-molecule multi-target TKIs.","FEMALE",{"count":50,"type":20},40,"INTERVENTIONAL",[53],"PHASE2","Ovarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers. Because no reliable tools exist for early detection, approximately 70 % of patients are diagnosed at an advanced stage and have poor prognosis, and \\>70 % experience relapse within 3 years of initial treatment. The standard first-line strategy combines cytoreductive surgery, platinum-based chemotherapy, and maintenance with PARP inhibitors. Management of recurrent disease remains one of the most challenging problems in clinical oncology.\n\nBevacizumab, a recombinant humanized anti-VEGF monoclonal antibody that blocks endothelial proliferation and neovascularization, is the prototypic angiogenesis inhibitor used in ovarian cancer. However, randomized trials have demonstrated only progression-free survival (PFS) benefit, with no overall survival (OS) advantage. Pre-clinical data suggest that immunotherapy and anti-angiogenic agents can exert synergistic anti-tumor activity, yet clinical efforts combining bevacizumab with immune-checkpoint inhibitors in recurrent ovarian cancer-whether added to platinum-based chemotherapy, used as maintenance, or evaluated in chemotherapy-free regimens-have thus far been unsuccessful (except in clear-cell histology).\n\nAnlotinib is a novel oral multi-target tyrosine-kinase inhibitor that blocks VEGFR-2\u002F3, FGFR 1-4, PDGFR-α\u002Fβ, c-KIT, and RET, thereby potently suppressing angiogenesis. Accumulating evidence indicates that anlotinib plus chemotherapy is more effective than chemotherapy alone in advanced or recurrent ovarian cancer, with a manageable safety profile, showing encouraging efficacy and tolerability.\n\nBecause conventional approaches for recurrent ovarian cancer are limited-particularly once platinum resistance develops-new therapeutic strategies are urgently needed. The best-characterized immune-checkpoint molecules are CTLA-4 and the PD-1\u002FPD-L1 axis. Combined blockade of CTLA-4 and PD-1 has yielded impressive activity in several tumor types. Although single-agent checkpoint inhibitors produce modest response rates in recurrent ovarian cancer, preliminary data suggest that dual inhibition with anti-CTLA-4 plus anti-PD-1 antibodies may enhance therapeutic responses.QL1706 is a novel dual-target immunotherapeutic agent that has been approved for second-line monotherapy in cervical cancer.QL1706, developed by Qilu Pharmaceutical using the proprietary MabPair™ platform, is the first bispecific antibody simultaneously targeting PD-1 and CTLA-4, showing synergistic anti-tumor activity and favorable tolerability.The treatment of recurrent ovarian cancer remains a formidable challenge; therefore, proactive exploration of diverse combination regimens is essential to achieve optimal therapeutic efficacy and maximize survival benefit for patients.",[56],"Treatment of Recurrent Ovarian Cancer","2025-12-03",{"date":59,"type":32},"2025-12-16",{"date":61,"type":32},"2025-11-15",{"date":63,"type":20},"2028-03-30",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":17,"enrollmentInfo":72,"targetDuration":4,"studyType":51,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":40},"100614950","phase-2-ql1706-plus-chemotherapy-as-neoadjuvant-therapy-for-locally-advanced-cervical-cancer-a-phase-ii-trial-100614950","NCT07286253","QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial","A Single-arm, Multicenter Phase II Clinical Study of QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cance","Inclusion Criteria:\n\n* (1) Has given written informed consent (or consent provided by an immediate family member if the subject is unable to do so) after full explanation of the study.\n\n  (2) Female, aged ≥ 18 and ≤ 70 years on the date of informed-consent signature. (3) Histologically confirmed cervical cancer: A. Squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; B. Previously untreated-no prior anti-cancer therapy for cervical cancer; C. FIGO 2018 stage IB3 or IIA2; D. Stage IIICr without involvement of the lower third of the vagina and without parametrial infiltration.\n\n  (4) At least one measurable lesion by CT or MRI per RECIST 1.1. Note: Lesions situated in a prior radiation field or previously treated by local-regional therapy must be classified as non-target lesions unless clear progression is documented or tumor viability is confirmed by biopsy, and no other measurable lesion exists; in that case the lesion may serve as a target lesion.\n\n  (5) Archival tumor tissue obtained within 5 years before enrollment OR a freshly obtained biopsy (≈ 7 unstained FFPE slides, minimum 5; preference for recent sample).\n\nThe biopsied lesion must not be selected as a RECIST 1.1 target lesion unless no other site is suitable and the biopsy was performed outside the screening period. If a subject cannot provide the required slides and the investigator judges re-biopsy to be unsafe, the number of slides may be reduced at the investigator's discretion.\n\n(6) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. (7) Life expectancy ≥ 12 weeks. (8) Adequate function of major organs documented within 14 days before randomisation (no transfusion, albumin, recombinant human thrombopoietin or colony-stimulating factors allowed during this period): Haematology Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL Platelets ≥100 × 10⁹\u002FL Haemoglobin ≥90 g\u002FL Hepatic Total bilirubin ≤1.5 × upper limit of normal (ULN) ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases present) Serum albumin ≥30 g\u002FL Renal Serum creatinine ≤1.5 × ULN; OR if \\>1.5 × ULN, calculated creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault) Coagulation APTT ≤1.5 × ULN PT\u002FINR ≤1.5 × ULN Cardiac Left-ventricular ejection fraction (LVEF) ≥50% Urinalysis Dipstick proteinuria \\\u003C2+ If ≥2+, 24-hour urine protein must be \\\u003C1.0 g to permit entry (9) Women of child-bearing potential must use a highly effective contraceptive method from informed-consent signature until 180 days after the last study-dose administration and must not be pregnant or lactating.\n\nExclusion Criteria:\n\n* (1) Prior exposure to any immunotherapy, including immune-checkpoint inhibitory antibodies (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4), immune-checkpoint agonistic antibodies (e.g., anti-ICOS, CD40, CD137, GITR, OX40), or cellular immunotherapy.\n\n  (2) Systemic or severe infection requiring intravenous antibiotics for \\>7 days within 2 weeks before enrolment, or unexplained fever \\>38.5 °C detected during screening or within 2 weeks prior to enrolment (fever judged by the investigator to be tumour-related is permitted).\n\n  (3) Systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressive agents (e.g., cyclophosphamide, azathioprine, methotrexate, thalidomide, TNF-α inhibitors) for any indication within 2 weeks before enrolment. Topical, nasal or inhaled corticosteroids are allowed; systemic steroids given solely for prophylaxis of contrast allergy are also permitted.\n\n  (4) Treatment with immunomodulatory agents such as thymosin, lentinan, interferon or interleukins within 2 weeks before enrolment.\n\n  (5) Use within 2 weeks before enrolment of aspirin (\\>325 mg\u002Fday), clopidogrel (\\>75 mg\u002Fday), dipyridamole, ticlopidine, cilostazol, or any therapeutic-dose anticoagulant other than low-molecular-weight heparin.\n\n  (6) Use of modern Chinese herbal preparations approved by NMPA for anti-cancer therapy within 2 weeks before enrolment.\n\n  (7) Major surgery, open biopsy or significant traumatic injury within 4 weeks before enrolment; or planned elective major surgery during the study. Local invasive procedures (e.g., core biopsy) within 1 week before enrolment are excluded, except for vascular-access device placement.\n\n  (8) Anti-cancer therapy (chemotherapy, endocrine therapy, targeted therapy, biological therapy, trans-arterial chemo-embolisation, etc.) within 4 weeks before enrolment.\n\n  (9) Symptomatic CNS metastases, leptomeningeal disease or spinal-cord compression at baseline. Asymptomatic subjects with stable CNS disease who have completed any prior CNS-directed therapy ≥2 weeks earlier and have been off corticosteroids and anti-convulsants for ≥2 weeks may be enrolled.\n\n  (10) Clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stenting.\n\n  (11) Recurrent third-space fluid (e.g., pleural effusion or ascites) requiring repeated drainage and judged poorly controlled.\n\n  (12) Active or potentially relapsing autoimmune disease, except: vitiligo, alopecia, psoriasis or eczema not requiring systemic therapy; hypothyroidism due to autoimmune thyroiditis on stable hormone replacement; or type 1 diabetes on stable-dose insulin.\n\n  (13) History of gastrointestinal or genitourinary perforation\u002Ffistula, or intra-abdominal abscess within 6 months before enrolment (subjects are eligible if the underlying defect has been surgically corrected).\n\n  (14) Bowel obstruction within 6 months before enrolment (subjects with incomplete obstruction that has resolved after treatment may be enrolled at the investigator's discretion), active intra-abdominal inflammation (including but not limited to peptic ulcer, diverticulitis or colitis).\n\n  (15) Clinically significant cardiovascular disorders:\n  1. Myocardial infarction, unstable angina, pulmonary embolism or other arterial\u002Fvenous thrombo-embolic or cerebrovascular event requiring medical intervention within 6 months before enrolment;\n  2. NYHA class III-IV congestive heart failure;\n  3. Serious arrhythmia requiring medication;\n  4. Mean QTcF \\>470 ms on 12-lead ECG (Fridericia formula) at screening. (16) Co-existing conditions that would increase the risk of adverse events during the study:\n\n  \u003C!-- -->\n\n  1. Poorly controlled hypertension (systolic \\>150 mmHg and\u002For diastolic \\>100 mmHg) despite optimal therapy;\n  2. Prior hypertensive crisis or hypertensive encephalopathy;\n  3. History of intracranial or spinal haemorrhage;\n  4. Bleeding diathesis, severe coagulopathy (off anticoagulation) or tumour encasing major vessels;\n  5. Haemoptysis ≥½ teaspoon bright-red blood per episode, radiation enteritis\u002Fcolitis or radiation cystitis with bleeding within 3 months before enrolment;\n  6. Evidence of free intra-abdominal air;\n  7. Serious non-healing or dehiscent wound or untreated fracture;\n  8. Any other condition judged by the investigator to confer unacceptable risk. (17) Interstitial lung disease, pneumoconiosis, drug-related pneumonitis or severely impaired pulmonary function that might interfere with detection or management of suspected drug-related pulmonary toxicity.\n\n     (18) HIV-positive; active hepatitis B (HBsAg-positive and HBV-DNA \\>500 IU\u002FmL, or above local lower limit of detection if \\>500 IU\u002FmL); active hepatitis C (subjects with positive HCV antibody but HCV-RNA below local lower limit of detection are eligible).\n\n     (19) Known active tuberculosis; known active syphilis. (20) Other active malignancy within 5 years before informed consent, except adequately treated localised cancers (e.g., basal- or squamous-cell skin cancer, superficial bladder cancer, ductal carcinoma in situ of the breast).\n\n     (21) Prior allogeneic haematopoietic stem-cell or organ transplantation (corneal transplant allowed).\n\n     (22) Live-vaccine administration within 4 weeks before enrolment. (23) Participation in another clinical trial and receipt of an investigational product within 4 weeks before enrolment.\n\n     (24) History of substance abuse (drugs or alcohol) or psychiatric\u002Fneurological disorder (epilepsy, dementia, hepatic encephalopathy, etc.) that could compromise compliance.\n\n     (25) Known hypersensitivity to macromolecular protein preparations, or contraindication\u002Fallergy to any component of QL1706, cisplatin\u002Fcarboplatin or paclitaxel.\n\n     (26) Any condition that, in the opinion of the investigator, could increase study-related risk or interfere with interpretation of results.",{"count":73,"type":20},50,[53],"Cervical cancer ranks as the second most common malignancy of the female genital tract. According to the World Health Organization, there are 530,000 new cases and approximately 250,000 cervical-cancer-related deaths worldwide each year, with 80% of these deaths occurring in women from developing countries. Early-stage disease can be managed surgically, whereas advanced or recurrent cervical cancer is treated with individualized multimodal therapy; nevertheless, the optimal management of locally advanced cervical cancer (FIGO 2018 stage IB3-IIA2) remains controversial. Chemoradiation is standard, but neoadjuvant chemotherapy followed by radical surgery after tumor down-staging is also used. More than 90% of cervical cancers are driven by persistent infection with high-risk human papillomavirus (HPV), which evades host immunity in part by up-regulating PD-L1 on tumor cells. Published series report PD-L1 positivity in 34.4-96% of cervical cancers, with even higher rates in squamous-cell histology, providing a rationale for PD-1\u002FPD-L1 blockade. QL1706, a novel bispecific immunotherapeutic agent, has recently been approved as monotherapy for second-line treatment of advanced cervical cancer.QL1706, developed by Qilu Pharmaceutical using the proprietary MabPair™ platform, is the first bispecific antibody simultaneously targeting PD-1 and CTLA-4, showing synergistic anti-tumor activity and favorable tolerability.Unlike previous phase II\u002FIII trials of PD-1 monotherapy, this study does not restrict enrolment to patients with PD-L1-positive tumors, so QL1706 is expected to confer benefit in the second-line management of recurrent or metastatic cervical cancer. Therefore, investigating QL1706-based combination regimens as neoadjuvant treatment for treatment-naïve disease is also highly relevant and may improve outcomes in women with locally advanced cervical cancer.",[77],"Neoadjuvant Treatment for Locally Advanced Cervical Cancer",{"date":59,"type":32},{"date":80,"type":32},"2025-10-28",{"date":63,"type":20},{"name":38,"class":39},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":51,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100561746","phase-2-early-application-of-memantine-and-pioglitazone-to-protect-cognitive-function-after-radiotherapy-100561746","NCT06594172","Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","A Phase II Clinical Trial of of Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","Inclusion Criteria:\n\n* Recursive Partitioning Analysis (RPA), Class I \\~ Class II\n* Karnofsky Performance Status of ≥70\n* The primary tumor must be pathologically confirmed. For newly diagnosed brain metastases, the number of metastases is not limited, but the brain metastases could not have been within 5 mm of hippocampus. Additionally, there must be no hard or soft meningeal metastases.\n* No history of whole-brain radiation therapy; patients who are eligible for surgical resection of brain metastases prior to radiation therapy are allowed.\n* Bone marrow function: White blood cell count ≥ 4 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL, and platelet count ≥ 100 × 10⁹\u002FL.\n* Adequate hepatic function: Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal); ALT (alanine aminotransferase), AST (aspartate aminotransferase) ≤ 2.5 × ULN; ALP (alkaline phosphatase) ≤ 2.5 × ULN and total bilirubin ≤ ULN.\n* Adequate renal function: creatinine clearance rate ≥ 30 ml\u002Fmin.\n* Patients or their legal guardians voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Radiographic evidence of hydrocephalus or other architectural distortion of the ventricular system, including placement of external ventricular drain or ventriculoperitoneal shunt.\n* Planned cytotoxic chemotherapy during the WBRT.\n* Pregnant or lactating women (Women of childbearing age must undergo a pregnancy test; effective contraception must be enforced during the treatment period).\n* Previous cranial radiation therapy (Except for patients with head and neck cancer where the disease site is outside the cranial radiation field).\n* Severe or active symptomatic cardiopulmonary diseases; clinically significant psychiatric disorders; Personality or psychiatric disease; Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease;\n* Intolerant to or allergic to Memantine or pioglitazone.\n* Difficulty swallowing, chronic diarrhea, or bowel obstruction.\n* NYHA class III or IV heart failure or symptomatic peripheral edema (grade 2 or higher); those treated with insulin or oral hypoglycemic agents for steroid-induced hyperglycemia, or those currently using other NMDA antagonists.","65 Years",{"count":92,"type":20},67,[53],"This clinical trial aims to evaluate the efficacy of early intervention with Memantine and Pioglitazone in preventing Radiation-Induced Brain Injury (RIBI) in patients undergoing cranial radiotherapy.\n\nRIBI, a significant complication of radiation therapy for primary and metastatic brain tumors, as well as head and neck cancers, often presents with delayed and irreversible neurological damage, severely affecting patients' quality of life.\n\nOur previous studies have indicated that Memantine, an NMDAR antagonist, and Pioglitazone, a PPAR-γ agonist, play crucial roles in modulating the neuroprotective immune microenvironment by targeting key mechanisms of neuron-astrocyte fatty acid metabolism coupling. These findings suggest that early administration of these drugs could protect cognitive function and reduce neuroinflammation in patients post-radiation.\n\nThis prospective phase II clinical trial will assess the combined efficacy of Memantine and Pioglitazone in improving cognitive outcomes and preventing RIBI without adversely impacting the anti-tumor efficacy of radiation therapy. The study will also explore the synergistic effects of these two FDA-approved drugs in early-stage RIBI prevention, providing a new therapeutic strategy for enhancing the quality of life in cancer patients receiving radiotherapy.",[96,97,98],"Radiation Disease","Cognitive Impairment","Drug Effect",[100,101,102,103],"radiation induced brain injury","Memantine","Pioglitazone","cognitive function","NOT_YET_RECRUITING","2024-09-16",{"date":107,"type":32},"2024-09-19",{"date":109,"type":20},"2024-09-10",{"date":111,"type":20},"2027-06-30",{"name":38,"class":39},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":121,"targetDuration":4,"studyType":51,"phases":123,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100559930","early-phase-1-analgesic-efficacy-of-an-opioid-free-postoperative-pain-management-strategy-versus-a-conventional-opioid-based-strategy-following-video-assisted-thoracoscopic-lobectomy-100559930","NCT06570538","Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy","Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy: an Open-label, Randomized, Controlled, Non-inferiority Trial","Inclusion criteria:\n\n* Aged between 18 and 65 years.\n* Patients with lung cancer or suspected lung cancer who are undergoing lobectomy surgery via Video-assisted thoracoscopic surgery (VATS) or Robotic-assisted thoracoscopic surgery (RATS).\n* American anesthesiologist association (ASA) physical status classificationⅠ-Ⅲ.\n* Surgery is expected to last at least 2 hours, with a minimum of 2 days of postoperative hospitalization.\n* Patients participate voluntarily and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Patients who underwent open-heart surgery.\n* Patients with BMI ≥30 kg\u002Fm², or ≤18.5 kg\u002Fm².\n* Patients who are allergic to any of the local anesthetic drugs, such as ropivacaine, lidocaine, bupivacaine, procaine, bupivacaine, benzocaine, dacronin, etc.\n* Patients who are allergic to any of the general anesthesia drugs, such as those including propofol, sufentanil, remifentanil, etc.\n* Patients who currently have active ulcers or have gastrointestinal bleeding or who are allergic to any NSAIDs such as parecoxib sodium, flurbiprofenol ester, and acetaminophen.\n* Patients with contraindications to epidural spinal plane block (ESPB), such as skin infection near the puncture site or coagulation disorders.\n* Patients allergic to ultrasound gel.\n* Patients with significant preoperative renal insufficiency (creatinine more than twice the upper limit of normal).\n* Patients with severe spinal deformities prior to surgery.\n* Patients with preoperative distant tumor metastasis.\n* Patients who have experienced cardiovascular or cerebrovascular accidents within the past six months.\n* Patients with unstable angina, ischemic myocardial infarction, or heart failure in the last six months.\n* Patients with severe preoperative lung disease (such as pulmonary fibrosis, severe lung abscess, pulmonary heart disease; or with FEV1 less than 50% of the predicted value, PaO2 ≤ 60 mmHg, PaCO2 \\> 50 mmHg).\n* Patients with poorly controlled preoperative hypertension or diabetes mellitus.\n* Patients with a past history of dementia, psychosis, or other neurological disorders.\n* Patients undergoing concurrent treatment for other surgical conditions.\n* Patients taking sedatives, antidepressants, or hormonal medications.\n* Patients with chronic pain, alcoholism, or drug dependence.\n* Patients who are pregnant or breastfeeding\n* Patients with other potentially serious medical conditions.\n* Patients who are unable to understand Mandarin or Cantonese.\n* Patients who participated in other clinical trials in the past 3 months\n* Patients who refuse to participate in the study or sign the informed consent form.",true,{"count":122,"type":20},140,[124],"EARLY_PHASE1","Investigators have designed a randomized controlled trial. Utilizing an open-label, randomized, controlled study methodology, this trial aims to explore a opioid-free, safe, and effective analgesic approach for thoracic surgery. It also seeks to provide clinical guidance for the implementation of opioid-free or reduced-opioid postoperative analgesia in other thoracic procedures, aiming to optimize postoperative pain management for patients and ultimately enhance the overall patients recovery experience.",[127],"Postoperative Pain",[129,130,131,132],"Lung Cancer","Postoperative pain","OFA","Erector spinae plane block","2024-08-22",{"date":135,"type":32},"2024-08-26",{"date":137,"type":20},"2024-09-01",{"date":139,"type":20},"2025-06-30",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":51,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100541290","phase-3-hivec-in-patients-with-non-muscle-invasive-bladder-cancer-100541290","NCT06327932","HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer","A Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intravesical Chemotherapy After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n1. Patients who did not receive induction perfusion within 4 weeks after complete resection of bladder tumor with TURBT (Patients who were judged by the investigator to be in need of secondary electrotomy, for the last time).\n2. Recurrence risk and prognosis of Non-Muscle-Invasive Bladder Cancer were divided into medium-risk group or high-risk group (patients who underwent multiple electrosurgical biopsies, and the pathological results were based on higher grade tumors).\n3. KPS score ≥80, expected survival \\> 30 months.\n4. Pathological suggested non-myoinvasive urothelial carcinoma of the bladder.\n5. Age between 18 and 70 years, all genders.\n6. Volunteer to participate in this clinical trial and written informed consent.\n\nExclusion Criteria:\n\n1. Patients with bladder cancer in situ.\n2. Combined with proven upper urinary tract or urethral tumors.\n3. The patients were complicated with bladder perforation, gross hematuria or urinary tract infection of grade 3-4.\n4. Patients with urethral discontinuity, urethral stricture, or inability to use a three lumen catheter normally affect perfusion therapy.\n5. Patients who had undergone partial cystectomy or abnormal bladder structure were judged by the investigator to be unsuitable for perfusion therapy.\n6. Patients with severe coagulation dysfunction.\n7. A history of allergy to injected drugs (gemcitabine).\n8. History of pelvic radiation, systemic chemotherapy, or immunotherapy.\n9. Complicated with cardiovascular, cerebrovascular, hematopoietic, immune system and other serious diseases.\n10. Patients with mental illness, substance abuse, alcoholism, and inability to cooperate.\n11. Breastfeeding, pregnant, or planning to have a baby in the near future.\n12. Recurrent patients with a prior history of BCG or bladder thermoperfusion therapy.\n13. Participated in other clinical trials 1 month before the trial.\n14. Vesicoureteral regurgitation.\n15. The investigator considered it inappropriate to participate in this clinical trial.","80 Years",{"count":150,"type":20},320,[152],"PHASE3","The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or high-risk group Non-Muscle-Invasive Bladder Cancer (NMIBC).",[155],"Non-Muscle-Invasive Bladder Cancer",[155,157,158],"Hyperthermic Intravesical Chemotherapy","recurrence rate","2024-03-18",{"date":161,"type":32},"2024-03-25",{"date":163,"type":20},"2024-04-01",{"date":165,"type":20},"2028-03-31",{"name":38,"class":39},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":51,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100489082","phase-2-hipec-combined-with-sintilimab-for-gastric-cancer-with-peritoneal-metastasis-100489082","NCT05648487","HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis","A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;\n2. Age 18-75 years, Male or Non pregnant female\n3. ECOG (Eastern Cooperative Oncology Group) : 0\\~1；\n4. Negative for HER-2 by IHC\u002FFISH；\n5. Peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；\n6. Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy);\n7. Normal Bone marrow, liver and kidney function indices before the recruitment:\n8. Expected survival≥ 12 week\n9. Signed the Informed Consent Form, and blood and tissue samples can be obtained;\n\nExclusion Criteria:\n\n1. Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);\n2. Previous systemic therapy for gastric cancer;\n3. Recurrent gastric cancer after surgery;\n4. Cardiopulmonary dysfunction;\n5. Immunosuppressive drugs(eg.Corticosteroids) were used within 14 days before treatment, eg.corticosteroids,\n6. There is any active autoimmune disease or a history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma in childhood have been completely relieved, and those who do not need any intervention after adulthood can be included Asthma requiring medical intervention with bronchodilator was not included.)\n7. Allergy to the drugs in this protocol；\n8. Patients with other diseases not suitable for inclusion, such as immune deficiency, active tuberculosis, hepatitis B (non-active hepatitis B surface antigen (HBsAg) carriers, hepatitis B virus titer \\\u003C500IU\u002Fml after treatment and with normal liver function can be included), hepatitis C virus positive;\n9. A history of idiopathic pulmonary fibrosis, tissue pneumonia, drug pneumonia, idiopathic pneumonia, or r active pneumonia;\n10. Other patients who were considered unsuitable for inclusion by the researchers;","75 Years",{"count":176,"type":20},46,[53],"To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.",[180],"Gastric Cancer",[180,182,183,184],"Peritoneal Metastasis","HIPEC","PD1","2022-12-14",{"date":187,"type":32},"2022-12-16",{"date":189,"type":20},"2023-01-01",{"date":191,"type":20},"2027-12-31",{"name":38,"class":39},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":174,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":210,"locationsCount":4},"100490052","biomarker-analysis-of-hipec-combined-with-pd1pdl1-inhibitor-for-gastric-cancer-with-peritoneal-metastasis-100490052","NCT05661110","Biomarker Analysis of HIPEC Combined With PD1\u002FPDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis","Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1\u002FPDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Advanced gastric (gastroesophageal junction) adenocarcinoma confirmed by histology;\n2. Age 18-75 years, Male or Non-pregnant female\n3. Eastern Cooperative Oncology Group(ECOG): 0\\~1；\n4. Negative for human epidermal growth factor receptor 2(HER-2) by immunocytochemistry or fluorescence in situ hybridization；\n5. The presence of gastric cancer peritoneal metastasis is confirmed by laparoscopic exploration, and the PCI≤20；\n6. Patients had received HIPEC combined with PD1\u002FPDL1 inhibitor conversion therapy.\n7. Signed the Informed Consent Form, and blood and tissue samples can be obtained;\n\nExclusion Criteria:\n\n1. Other distal metastases besides peritoneal metastases (e.g., liver, lung, pleural, brain, bone metastases, etc.);\n2. Other patients who were considered unsuitable for inclusion by the researchers;",{"count":176,"type":20},"A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 \u002FProgrammed cell death 1 ligand 1(PD1\u002FPDL1)inhibitor in previously treated patients of advanced gastric cancer with peritoneal metastasis. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.",[180],[204],"Biomarker","2022-12-13",{"date":207,"type":32},"2022-12-22",{"date":189,"type":20},{"date":191,"type":20},{"name":38,"class":39},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":218,"targetDuration":4,"studyType":51,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100476488","phase-2-durvalumab-combined-with-consolidation-radiotherapy-after-first-line-treatment-in-extensive-stage-small-cell-lung-cancer-with-oligometastases-100476488","NCT05484583","Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases","Prospective Phase ii Clinical Study of the Efficacy and Safety of Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment With Platinum-containing Chemotherapy in Extensive Stage Small Cell Lung Cancer With Oligometastases (1-5 Lesions)","1. Histology or cytology confirmed small cell lung cancer\n2. The number of metastatic lesions is less than 5 (oligometastatic)\n3. According to the seventh edition of the American Joint Cancer Board, IV or T3-4 cannot be included in the same tolerable radiation program due to the widespread distribution of multiple lung nodules or the large size of tumors \u002F lymph nodes.\n4. Four to six cycles of Durvalumab combined with standard chemotherapy (platinum + etoposide) were evaluated as CR（complete response） or PR（partial response） before entering the group.\n5. Radiation oncologists determine that chest and oligometastatic lesions can be treated with radiotherapy.\n6. The age of diagnosis was 18 to 70 years old.\n7. The Eastern Cooperative Oncology Group physical fitness score (PS score) was 0-1.\n8. The function of bone marrow was normal: White blood cell count ≥ 3 × 10\\^9\u002FL, neutrophil count ≥ 1.5 × 10\\^9\u002FL, hemoglobin concentration ≥ 90g\u002FL, platelet count ≥ 100 × 10\\^9\u002FL.\n9. Normal liver and kidney function: total bilirubin ≤ 1.5 times normal upper limit; glutamic oxaloacetic transaminase and \u002F or glutamic pyruvic transaminase ≤ 2.5 times normal upper limit; alkaline phosphatase ≤ 2.5 times normal upper limit; creatinine clearance ≥ 60 mL\u002Fmin.\n10. Life expectancy ≥ 12 weeks\n\nExclusion Criteria:\n\n1. Within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is the longer), systemic immune stimulants (including but not limited to interferon, interleukin-2, tumor necrosis factor) are used (cancer vaccines are allowed in previous treatments)\n2. Within 14 days before the first administration of the drug, any Chinese herbal medicine used to control cancer was used.\n3. Any disease that must be treated with corticosteroids (prednisone \\> 10mg\u002F days or equivalent) or other immunosuppressive drugs within 14 days before enrollment Note: patients who have used or have used any of the following steroid regimens can be selected: epinephrine replacement steroids (prednisone ≤ 10mg\u002F days or equivalent). Inhaled corticosteroids with very low local, ocular, articular, nasal or systemic absorption; prophylactic use of prescription corticosteroids in a short course (≤ 7 days) or for the treatment of non-autoimmune diseases (such as delayed anaphylaxis caused by contact allergens)\n4. Live vaccine is given within 4 weeks before joining the group. Note: seasonal influenza vaccine is usually an inactivated vaccine, and patients who receive such vaccine are allowed to join the group. The intranasal influenza vaccine is a live vaccine, and patients vaccinated with such vaccine are not allowed to enter the group.\n5. Any major surgery requiring general anesthesia was performed within 28 days before enrollment.\n6. Previous allogeneic stem cell transplantation or organ transplantation\n7. Clinically uncontrolled pericardial effusion or ascites requiring pleural or abdominal puncture drainage within 2 weeks before randomization. Uncontrolled brain metastasis with active leptomeningeal disease:\n8. patients with asymptomatic central nervous system (CNS) metastasis during the screening phase can be selected if all of the following conditions are met: brain imaging examinations during the screening phase show that there is no evidence of mid-term progression between completion of immunotherapy combined with chemotherapy induction therapy and enrollment; no continuous use of corticosteroids for CNS disease; and permitting stable doses of anticonvulsant therapy.\n9. Suffer from active autoimmune diseases or have a history of autoimmune diseases that may recur. Note: patients with the following diseases can be further screened: well-controlled type 1 diabetic hypothyroidism (only thyroid hormone replacement therapy can be controlled); well-controlled celiac disease; any other diseases that do not require systemic treatment (such as vitiligo, psoriasis, alopecia) that are not expected to recur without external triggers\n10. Has suffered from interstitial lung disease or non-communicable pneumonia or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc.\n11. Severe chronic or active infections that require systemic antibacterial, antifungal or antiviral therapy within 2 weeks before enrollment, including, but not limited to, tuberculosis\n12. Any active malignant tumor less than 2 years before enrollment, except for specific cancers examined in this study and any locally recurrent cancers that have been cured (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ)\n13. Untreated chronic hepatitis B patients, chronic hepatitis B virus carriers with HBV DNA ≥ 500 IU \u002F mL (2500 copies \u002F mL), active hepatitis C patients: patients with inactive HBsAg carriers and patients with stable active HBV infection (HBVDNA \\\u003C 500 IU\u002FmL (2500 copies \u002F mL)) after drug treatment can be enrolled. Only patients with positive hepatitis B core antigen (anti-hepatitis B core antigen antibody) were tested for HBVDNA. Patients who were negative for hepatitis C virus (HCV) antibody during screening, or those who were positive for HCV antibody and then negative for HCV RNA test during screening could be included in the study. Only hepatitis C virus (HCV) antibody positive patients will be tested for HCVRNA. Note: patients who can detect hepatitis B surface antigen (HBsAg) or HBVDNA should be treated in accordance with treatment guidelines. Patients who received antiviral therapy at the time of screening should have been treated for more than 2 weeks before joining the group and continued treatment for 6 months after discontinuing the study drug treatment.\n14. he known history of HIV infection 16. is 16. 5%. There are any of the following cardiovascular risk factors: a. Cardiogenic chest pain occurred ≤ 28 days before randomization, which was defined as moderate pain limiting instrumental activities of daily life b. Symptomatic pulmonary embolism occurred ≤ 28 days before randomization. There was any history of acute myocardial infarction less than 6 months before randomization. There was a history of heart failure in New York Heart Association (NYHA) grade III or IV (Appendix 5) ≤ 6 months before randomization. Ventricular arrhythmias with severity ≥ 2 occurred less than 6 months before randomization. There was a history of cerebrovascular accident less than 6 months before randomization. Uncontrolled hypertension: ≤ 28 days before randomization, despite the use of antihypertensive drugs, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg. Syncope or seizures occurred less than 28 days before randomization.\n15. Patients with side effects (due to previous anticancer therapy) did not return to baseline or stable levels at the time of admission, except for adverse event (such as hair loss, neuropathy and specific laboratory abnormalities) that could not pose safety risks.\n16. Has a history of severe hypersensitivity to other monoclonal antibodies. 19.Suffering from underlying diseases (including abnormal laboratory tests) or alcohol or drug abuse or dependence, which are not conducive to the study of drug administration or affect the interpretation of drug toxicity or adverse event, or may lead to insufficient or reduced compliance with research behavior.\n17. At the same time, he participated in another therapeutic clinical study.",{"count":219,"type":20},58,[53],"In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide scientific basis for the formulation of the best comprehensive treatment plan in the future.",[129,223,224],"Extensive-stage Small-cell Lung Cancer","Radiotherapy","2022-08-03",{"date":227,"type":32},"2022-08-05",{"date":229,"type":20},"2022-08-01",{"date":231,"type":20},"2027-08-01",{"name":38,"class":39},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":240,"targetDuration":4,"studyType":51,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100476472","phase-2-capecitabine-plus-toripalimab-maintenance-therapy-in-metastatic-nasopharyngeal-carcinoma-after-first-line-treatment-100476472","NCT05484375","Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment","Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Gemcitabine\u002FCisplatin Plus Toripalimab Treatment: a Single Arm, Open Label, Multicenter, Phase II Clinical Study","Inclusion Criteria:\n\n1. Histology confirmed metastatic nasopharyngeal carcinoma following radical treatment（Stage IVb, AJCC\u002FUICC 8th，any T，any N，M1）\n2. Patients receiving gemcitabine\u002Fcisplatin in combination with terriprizumab received complete response (CR) or partial response (PR) after 4-6 cycles of imaging studies\n3. Age ≥18 years and ≤65 years\n4. WBC≥4×10\\^9\u002FL, platelet ≥ 100×10\\^9\u002FL, hemoglobin ≥ 90g\u002FL and Albumin≥28 g\u002FL\n5. With normal liver function test (TBIL#ALT#AST ≤ 2.5×uln) (patients with liver metastasis≤5×uln)\n6. With normal renal function test (creatinine ≤ 1.5×uln or CCR ≥ 60ml\u002Fmin)\n7. ECOG score is 0-1\n8. At least one measurable lesion according to RECIST v 1.1 (prior to gemcitabine\u002Fcisplatin plus toripalimab)\n9. Life expectancy is at least 12 weeks\n10. Patients sign informed consent forms\n\nExclusion Criteria:\n\n1. History of severe anaphylaxis to any component of capecitabine or toripalimab\n2. Active or untreated central nervous system metastases\n3. Patient with necrotic lesions and judged by the investigator to be at risk of excessive bleeding\n4. Patients with poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage. Patients with indwelled catheters are allowed to participate.\n5. Patients with poorly controlled or symptomatic hypercalcemia\n6. Pregnancy or lactation\n7. Malignancies other than nasopharyngeal carcinoma, with negligible risk of metastasis or death and radical outcome expected after treatment, within the 5 years prior to enrollment.\n8. Patients who have previously received allogeneic bone marrow transplants or solid organ transplants.\n9. History of autoimmune diseases\n10. Received systemic immunostimulant therapy (except toripalimab in palliative chemotherapy, including but not limited to interferon or IL-2) within 4 weeks prior to enrollment or during 5 half-lives of the drug.\n11. Receive any active vaccine within 4 weeks prior to enrollment\n12. Basic medical conditions that the investigator identified as likely to affect significantly drug administration and protocol adherence of the study\n13. Active pneumonia\n14. Active infections, including tuberculosis, hepatitis B, hepatitis C or HIV.\n15. Presence of severe neurological or psychiatric disorders, including dementia and seizures.\n16. Peripheral nerves which was graded as≥ 2 according to NCI-CTCAE\n17. Major cardiovascular diseases",{"count":50,"type":20},[53],"to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine\u002Fcisplatin combined with toripalimab.",[244],"Metastatic Nasopharyngeal Carcinoma",[246,247,248,249],"nasopharyngeal carcinoma","capecitabine","toripalimab","maintenance therapy","2022-07-30",{"date":252,"type":32},"2022-08-02",{"date":254,"type":20},"2022-09",{"date":256,"type":20},"2029-09",{"name":38,"class":39},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":265,"targetDuration":4,"studyType":51,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":40},"100396071","phase-3-nedaplatin-versus-cisplatin-in-treatment-for-nasopharyngeal-carcinoma-100396071","NCT04437329","Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","Nedaplatin Versus Cisplatin in Induction Chemotherapy Combined With Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma：a Prospective, Parallel, Randomized, Open Labeled, Phase III Non-Inferiority Clinical Study","Inclusion Criteria:\n\n1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III\n2. Original clinical staged as III-IVa (except T3-4N0) according to the 8th edition American Joint Committee on Cancer staging system\n3. No evidence of distant metastasis (M0)\n4. Age between 18-65\n5. WBC≥4×10\\^9\u002F l, platelet ≥ 100×10\\^9\u002F l and hemoglobin ≥ 90g\u002Fl\n6. With normal liver function test (TBIL、ALT、AST ≤ 2.5×uln)\n7. With normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml\u002Fmin)\n8. Satisfactory performance status: KARNOFSKY scale (KPS) \\> 70\n9. Patients must give signed informed consent\n\nExclusion Criteria:\n\n1. Histologically confirmed keratinizing nasopharyngeal carcinoma (WHO I)\n2. Age \\>65 or \\\u003C 18 years\n3. Treatment with palliative intent\n4. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer\n5. History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes\n6. History of previous radiotherapy\n7. Pregnancy or lactation\n8. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, active hepatitis, and mental disturbance",{"count":266,"type":20},352,[152],"To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.",[270],"Nasopharyngeal Carcinoma",[272,273,274,275],"induction chemotherapy","nedaplatin","cisplatin","concurrent chemoradiotherapy","2022-05-06",{"date":278,"type":32},"2022-05-10",{"date":280,"type":32},"2020-08-01",{"date":282,"type":20},"2029-06-30",{"name":38,"class":39},""]